MIRA
INFORM REPORT
|
Report Date : |
30.07.2007 |
IDENTIFICATION DETAILS
|
Name : |
|
|
|
|
|
Registered Office : |
Rm 712 Hing Wai Centre, 7 Tin Wan |
|
|
|
|
Country : |
|
|
|
|
|
Date of Incorporation : |
March 12, 2001 |
|
|
|
|
Com. Reg. No.: |
750047 |
|
|
|
|
Legal Form : |
Private Limited Company |
|
|
|
|
Line of Business : |
Trading a wide range of pharmaceutical products manufactured by its |
RATING & COMMENTS
|
MIRA’s Rating : |
B |
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
26-40 |
B |
Unfavourable & favourable factors carry similar weight in credit
consideration. Capability to overcome financial difficulties seems comparatively
below average/normal. |
Small |
|
Maximum Credit Limit : |
Up To USD 15,000 |
|
|
|
|
Status : |
Small Company |
|
|
|
|
Payment Behaviour : |
Usually correct |
|
|
|
|
Litigation : |
Clear |
name &
address
RM 712 HING WAI CENTRE
7 TIN WAN
TEL : 852-25559600
FAX : 852-25551135
EXECUTIVE SUMMARY
INCORPORATION DATE :
MARCH 12, 2001
REGISTRATION NO. :
750047
LEGAL FORM :
PRIVATE LIMITED COMPANY
CHIEF EXECUTIVE :
MR. KWOK-SING CHEUNG (CHAIRMAN)
STAFF STRENGTH :
5
CAPITAL :
US$ 797,954
BUSINESS LINE :
TRADER
TURNOVER :
N/A (AS OF DEC. 31, 2006)
EQUITIES :
N/A (AS OF DEC. 31, 2006)
PAYMENT :
AVERAGE
RECOMM.
MARKET CONDITION :
AVERAGE
FINANCIAL CONDITION :
N/A
OPERATIONAL TREND : STEADY
GENERAL REPUTATION :
AVERAGE
EXCHANGE RATE :
HKD 7.82137 = US$1 AS OF 2007-7-27
Adopted abbreviations:
ANS - amount not stated
NS - not stated
SC - subject company (the company inquired by you)
NA - not available
M - million
HKD –
*Company Registration*
===================
(1)
License number : 750047
Date issued : 12 March,
2001
Issuing authority : Companies
Registry
Type of license : Corporate
(2)
License number : 31660495
Date issued : N/A
Issuing authority : Business
Registration Office - Inland Revenue Dept
Type of license :
Business
*Capital Details*
=============
Authorized capital : HKD 6,240,000.00 divided into 6,240,000 ordinary
shares at HKD 1.00/-each, fully paid
*Reputation*
==========
Reference checking for the purpose of establishing the firm's reputation
within the respective industry failed to reveal any negative information.
*Approved Signatures*
=================
Only Mr. Kwok-sing Cheung can sign on behalf of the company with seal
affixed.
E-mail: tianjin.pharma@tjpchk.com
For the past two years there is no record of litigation.
*Major Shareholders*
=================
Total number of shareholders
: 3
Total number of ordinary shares
: 6,240,000
Shareholders' Name No. of
Shares Amount of Shares (HKD) % of Shares
---------------------------
-------------------
----------------------------------
------------------
Mr. Hong Wang
1,872,000
1,872,000.00 30.00
Mr. Kwok-sing Cheung 1,872,000 1,872,000.00 30.00
Share Transfer
--------------------
Transferor :
TIANJIN PHARMACEUTICALS GROUP CORP
Transferee :
TIANJIN TIANYAO PHARMACEUTICAL CO LTD
Amount transferred : HKD
2,496,00000
Date transferred : 12
March, 2007
*Director's Details*
=================
(1)
Mr. Shu-yan Wei
Address : 402
Wen Xing Garden - Block
(2)
Mr. Yu-tian Hao
Address : 109
Ba Wei Rd Hedong Dist
(3)
Mr. Shing-ngai Li
HKID no. : D106395(3)
Address : 6Fl Ping On Mansion
- Block B 1B Babington Path Mid-Level Hong Kong
(4)
Mr. Yan-chang Lu
HKID no. : K00812608
Address : 109 Ba Wei Rd
Hedong Dist
(5)
Mr. Hong Wang
Address : Rm
(6)
Mr. Fu-jun Wang
Address : 109 Ba
Wei Rd Hedong Dist
*Company Secretary*
=================
PIUS CONSULTING LTD
C. R. no. : 405723
Address : Rm B 16Fl Success Commercial Bldg 245-251 Hennessey Rd Wanchai
Hong Kong
*Key Personnel*
============
Mr. Kwok-sing Cheung
HKID no. : K233248(5)
Address : 17Fl
Responsibility : Handles the
overall management of the company.
*Main Products & Services*
======================
Specializes in trading a wide range of pharmaceutical products manufactured
by its
*Payment Terms*
=============
Sales
------
Local : Cash or Credit
Export : Letter of Credit (L/C)
Telegraphic Transfer
(T/T)
Purchases
--------------
Local : Cash or Credit
Import : Letter of Credit (L/C)
Telegraphic Transfer
(T/T)
*Local Distribution Network*
=======================
Part of the annual turnover is attributed to local sales.
*Export Markets*
==============
Part of the annual turnover is attributed to export.
SC is not known to have any subsidiary at
present.
PAYMENT RATING : 3 OBTAINED SCORES : 51
|
Implication |
Implications |
|
|
1 |
Scores 85–100 |
Excellent |
|
2 |
Scores 75 – 84 |
Above Average |
|
3 |
Scores 50 – 74 |
Average |
|
4 |
Scores 35 – 49 |
Fair |
|
5 |
Scores 15 – 34 |
Below Average |
|
6 |
Scores 01 – 14 |
Poor |
|
NR |
No Data |
No Data |
The rating indicates the payment
pattern of SC based upon our Payment Database, comments from suppliers of SC,
information from banks (if available), as well as industrial sources.
Dealings on open terms may be possible for SMALL amounts
depending on individual judgement experience.
As a private limited company there is no legal requirement according to
local corporate law for public disclosure of detailed financials.
SC is considered small-sized in its line locally. It is considered a credit line up to USD
15,000 appears to be within SC’s capacities.
Attached:
trade references
SIC PRODUCT CLASSIFICATION & ACTIVITY
Activity Code Product/Service Description
Trading 2834 Pharmaceutical
preparations
HARMONIZED PRODUCT CLASSIFICATION & ACTIVITY
Activity Code Product/Service Description
Trading 3000 Pharmaceutical
products
INTERNATIONAL
TRADE: ACTIVITY & MARKETS
Exporting to
Exporting to
Exporting to
Exporting to
Exporting to
Importing from
Importing from
RATING EXPLANATIONS
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
>86 |
Aaa |
Possesses an extremely sound financial base with the strongest capability
for timely payment of interest and principal sums |
Unlimited |
|
71-85 |
Aa |
Possesses adequate working capital. No caution needed for credit
transaction. It has above average (strong) capability for payment of interest
and principal sums |
Large |
|
56-70 |
A |
Financial & operational base are regarded healthy. General
unfavourable factors will not cause fatal effect. Satisfactory capability for
payment of interest and principal sums |
Fairly Large |
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
26-40 |
B |
Unfavourable & favourable factors carry similar weight in credit
consideration. Capability to overcome financial difficulties seems comparatively
below average/normal. |
Small |
|
11-25 |
Ca |
Adverse factors are apparent. Repayment of interest and principal sums
in default or expected to be in default upon maturity |
Limited with
full security |
|
<10 |
C |
Absolute credit risk exists. Caution needed to be exercised |
Credit not
recommended |
|
NR |
In view of the lack of information, we have no basis upon which to
recommend credit dealings |
No Rating |
|
This score serves as a reference to assess SC’s credit risk
and to set the amount of credit to be extended. It is calculated from a
composite of weighted scores obtained from each of the major sections of this
report. The assessed factors and their relative weights (as indicated through
%) are as follows:
Financial
condition (40%) Ownership
background (20%) Payment
record (10%)
Credit history
(10%) Market trend
(10%) Operational
size (10%)